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Introduction
Colorectal cancer (CRC) usually metastasizes to the liver 
(almost half of patients undergoing primary CRC resec-
tion will develop metachronous liver metastases and a 
quarter of patients diagnosed with CRC have synchronous 
hepatic secondaries) [1, 2]. The lung is the most common 
extrahepatic site of metastases accounting for a 10–20% 
metastatization rate [2, 3]. Lung recurrence occurs in 
5–10% of patients who undergo surgery for localized CRC 
[4]. Rectal cancer has a higher incidence of both syn-
chronous (2.8- fold increase in 5 years) and metachronous 
(2.63- fold increase) pulmonary metastasization compared 
to colon cancer [3].
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Abstract
KRAS mutant colorectal cancer (CRC) patients develop lung and brain metas-
tases more frequently than KRAS wild- type (WT) counterpart. We retrospectively 
investigated the prognostic role of KRAS, BRAF, and PIK3CA (exon 20) muta-
tions and loss of phosphatase and tensin homolog (PTEN) in surgically resected 
lung metastases. Lung specimens from 75 metastatic CRC (mCRC) patients 
treated with one or more metastasectomies with curative intent were analyzed. 
Sixty- four percent of patients had KRAS WT lung metastases. PTEN loss- of- 
function was found in 75%. BRAF and PIK3CA exon 20 mutations were not 
found. Seven patients subsequently developed brain metastases and 43% of them 
had KRAS mutation. In univariate analysis, median overall survival (OS) for 
KRAS WT patients was longer, compared to KRAS mutant patients (median 
60.9 vs. 36.6 months, P = 0.035). In addition, both progression- free survival 
(PFS) and lung disease- free survival (LDFS) between lung surgery and relapse 
were not associated with KRAS and PTEN status. In multivariate analysis, the 
risk of death was significantly increased by KRAS mutational status (OS Hazard 
ratio (HR) 2.17, 95% IC 1.19–3.96, P = 0.012) and lack of adjuvant chemo-
therapy (OS HR 0.10, 95% IC 0.01–0.74, P = 0.024). The proportion of KRAS 
mutations in lung metastases was similar to the expected proportion in primary 
tumors. Patients harboring KRAS mutation had a poorer survival rate compared 
to WT group both in univariate and multivariate analysis. Moreover, adminis-
tration of adjuvant chemotherapy after lung metastasectomy (LM) significantly 
improved both PFS and OS. KRAS mutation is a negative prognostic factor in 
mCRC patients undergoing LM. Further larger and prospective studies are nec-
essary to confirm these findings.
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Several clinical factors, including a short disease- free 
interval between the diagnosis of primary tumor and onset 
of lung metastases, multiple lung metastases (two or more), 
mediastinal and hilar lymph node involvement and elevated 
prethoracotomy serum carcinoembryonic antigen (CEA) 
levels, have been associated with reduced survival after 
pulmonary metastasectomy in patients with CRC [5].
Lung metastasectomy (LM) has become a widely  accepted 
and safe procedure in the management of metastatic CRC 
(mCRC). Indeed, surgical practice has improved results 
obtained with stage IV palliative chemotherapy by 
 increasing the 5- year survival rate to more than 50% of 
patients with isolated pulmonary metastases, with an 
 attested operative mortality of <1% [6, 7].
Despite the presence of clinical prognostic factors, none 
of the known molecular biomarkers has been clearly cor-
related with the prognosis of mCRC with lung metastases. 
Recently, it has been reported that patients with KRAS 
mutant CRC more frequently develop lung [8–15] and brain 
metastases [9, 11]. KRAS mutational status has been reported 
as a negative prognostic factor in many studies in early 
stage and mCRC [16–19]. Several reports are available on 
the negative prognostic role of both KRAS and BRAF muta-
tion in patients undergoing liver resection [20–22].
Few series have focused on the negative prognostic role 
of KRAS mutation in the subset of patients with lung 
metastases [8–15] and a recent series identified BRAF 
mutation as a significant negative prognostic factor as 
well [12]. On the other hand, PI3KCA mutations were 
not found to have any prognostic implication in this se-
lected cohort of patients [9, 11] while the role of phos-
phatase and tensin homolog (PTEN) loss has not been 
evaluated yet.
Here, we investigate the incidence and prognostic role 
of a panel of molecular biomarkers such as KRAS, BRAF, 
and PIK3CA (exon 20) mutations and loss of PTEN in 
a cohort of patients with mCRC undergoing LM.
Material and Methods
We retrospectively reviewed the medical records of all 
patients treated with surgery for lung metastases from 
CRC at Humanitas Cancer Center, Rozzano, Milan, Italy, 
between 1997 and 2009. The study was approved by the 
Institutional Review Board. Patients were included in the 
analysis if (1) they had had a diagnosis of CRC (2) they 
had suffered from the development of synchronous or 
metachronous lung metastases (3) they had undergone 
one or more lung metastasectomies (4) pulmonary resec-
tion had been performed with a curative intent (5) tissue 
specimen of the pulmonary resection documented a di-
agnosis of mCRC and was available for molecular analyses. 
Lung metastases diagnosed within 6 months of the initial 
diagnosis of CRC were considered as synchronous [23]. 
Both adjuvant chemotherapy for patients developing me-
tachronous metastases and first- line treatment for syn-
chronous lung lesions were considered. For all patients 
fulfilling the inclusion criteria, we collected the following 
clinical characteristics: sex, date of birth and age, date of 
diagnosis and site of primary tumor, pathological tumor- 
node- metastasis and stage, date of diagnosis and sites of 
metastatic disease, number and site of lung lesions (left, 
right, unilateral or bilateral), number and type of systemic 
lines prior to lung surgery, type of adjuvant therapy, dis-
ease status before lung surgery (partial response, stable 
disease, progressive disease), date of lung surgery, outcome 
after surgery (relapse–nonrelapse), date of relapse, number 
and type of systemic lines of treatment after surgery, and 
date of last contact or death. We did not consider pre-
thoracotomy serum CEA levels firstly because of the scarce 
reproducibility of dosages obtained in different laboratories 
and secondly because CEA elevation can be lacking in 
the setting of metastatic CRC to lungs. Indeed, prior 
studies have suggested that only 15% of patients with 
solitary lung metastases have a CEA elevation [24].
We evaluated the clinical outcome with respect to KRAS, 
BRAF, and PIK3CA exon 20 mutational status and loss 
of PTEN function in lung metastases.
PTEN expression was assessed by immunohistochemistry 
(IHC) using a monoclonal antibody (clone 6H2.1, 1:200; 
BioCare Medical, Concord, CA, USA), on 3 μm thick 
tissues section. Results were expressed using a binary scor-
ing system: positive PTEN expression was defined as 
staining in more than 10% of tumor cells, as previously 
reported (Fig. 1) [25].
KRAS (codon 12, 13, and 61) and PIK3CA exon 20 mu-
tations were assessed in DNA extracted from paraffin- 
embedded sections by direct sequencing. Each exon was 
amplified and sequenced. PCRs were performed in 50 μL 
volumes containing 100 ng genomic DNA, 1× PCR buffer, 
1.5 mmol/L MgCl2, 0.2 mmol/L each dATP, dCTP and 
dTTP, 0.2 μmol/L each primer, and 0.5 units of Taq poly-
merase (Genespin, Milan, Italy). PCR products were purified 
with ExoSap- it (USB® Products; Affymetrics Inc., Santa Clara, 
CA, USA) following the manufacturer’s instructions. Finally, 
10 μL of purified single- strand DNA was submitted to se-
quencing analysis on the ABI PRISM 310 Genetic Analyzer 
(Applied Biosystems, Foster City, CA, USA). Each sequence 
was carried out at least twice, starting from an independent 
amplification reaction. The oligonucleotide primers used for 
amplifying the KRAS codon 12 and 13 were 5′- TTATT 
ATAAGGCCTGCTGAAAATG- 3′ (sense) and 5′CCTCTATT 
GTTGGATCATATTCGT- 3′ (antisense); for KRAS codon 61 
were 5′- GGAAGCAAGTAGTAATTGATGGAG- 3′ (sense) 
and 5′- TTTATGGCAAATACACAAAGAAAG- 3′ (antisense). 
PI3KCA exon 20 was analyzed with 2 overlapping fragments 
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(A and B): forward A primer was 5′- TCATTTGCTCCAAA 
CTGACC- 3′ while reverse A primer was 5′- ACTCC 
AAAGCCTCTTGCTCA- 3′; forward B primer was 5′- CTC 
AATGATGCTTGGCTCTG- 3′ and reverse B primer 5′- TGG 
AATCCAGAGTGAGCTTTC- 3′.BRAF V600E mutation was 
determined by Real- Time PCR using a TaqMan SNP 
Genotyping Assay (Applied Biosystem) on DNA extracted 
from paraffin- embedded sections. TaqMan MGB probes were 
designed using the Custom TaqMan Assay Design Tool 
(Applied Biosystem). The chosen reporter fluorophores were 
VIC for detecting the wild- type (WT) allele and FAM for 
the mutant allele [26].
Statistical analysis
Differences in the distribution of demographics and clinic- 
pathological characteristics between the molecular groups 
of interest were evaluated using the Chi- square test, or 
the Fisher’s exact test, as appropriate. Overall survival 
(OS) was calculated from the time of first pulmonary 
surgery to death (if alive, patients were censored at the 
time of the last contact). Progression- free survival (PFS) 
was calculated from the time of first LM as well. Lung 
disease- free survival (LDFS) was calculated between the 
date of surgery of primary tumor and lung relapse [23].
Actuarial survival curves were generated using the 
Kaplan–Meier method and differences between groups 
were estimated using the log- rank test. A multivariable 
model was built to correct for the effect of confounders. 
Hazard ratio (HR) with its corresponding 95% confidence 
interval was calculated using the Cox Proportional Hazard 
Model. P- value for statistical significance was set at <0.05. 
All the analyses were performed using R- software (R 
foundation for statistical Computing, Wien, Austria).
Results
Patient characteristics
The main patients’ characteristics are reported in Table 1. 
Seventy- five patients were included. Median age at 
diagnosis was 65.4 years (range 33.4–80.1). Sixty patients 
(80%) had extrapulmonary disease of which 28 (37%) 
had liver metastases. Liver metastasectomy was performed 
in 25 cases. Only in two cases, a combined hepatic and 
pulmonary surgery was performed. Twenty (28%) patients 
had synchronous lung metastases while 53 (72%) developed 
metachronous pulmonary disease. In two cases (2%), time 
of development of lung metastases was not known. Twenty- 
one patients (28%) underwent more than one surgery 
for metastases. Median number of lung metastases was 
1 (range 1–10). Thirty patients (40%) developed right- 
sided metastases only while 30 cases (40%) had left lung 
Figure 1. Phosphatase and Tensin Homolog immunohistochemistry (objective magnification 10 × ) (A) positive expression (B) negative expression.
A B
Table 1. Baseline patient characteristics.
Characteristics Number (%)
Sex
Female 48 (64)
Male 27 (26)
Age
Median, years (range) 65.4 (33.4–80.1)
Primary tumor
Colon 45 (60)
Rectum 30 (40)
Lung metastases
Synchronous 20 (27)
Metachronous 53 (71)
Unknown 2 (2)
Localization
Unilateral 60 (80)
Bilateral 15 (20)
Chemotherapy prior to lung surgery
Yes 40 (53)
No 35 (47)
Adjuvant chemotherapy
No 62 (89)
Yes 8 (11)
Extrapulmonary metastases
Yes 60 (80)
No 15 (20)
Nodal involvement
Yes 45 (60)
No 22 (29)
Unknown 8 (11)
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metastases only. In 15 cases (20%), both right and left- 
sided metastases were diagnosed. All LMs were R0 or R1. 
Forty patients (54%) received chemotherapy prior to lung 
surgery while 35 patients (46%) did not receive systemic 
treatment. Among patients treated with preoperative 
chemotherapy, 14 patients (35%) underwent lung resec-
tion after the stabilization of disease or a partial response, 
while the majority (26 patients, 65%) underwent surgery 
after progressive lung disease. Twenty- six patients (65%) 
received preoperative treatment either with FOLFOX or 
FOLFIRI, while the remaining had 5- fluorouracil and fo-
linic acid or other single- agent chemotherapies. Eight 
patients (10%) had adjuvant treatment either with FOLFOX 
regimen or 5- fluorouracil and folinic acid. Among these 
patients, 6 (75%) had primary surgery while 2 (25%) 
received also preoperative treatments. Fifty- four patients 
(72%) relapsed after lung surgery and 41 of them (76%) 
had a subsequent systemic treatment. In 21 cases, KRAS 
mutational status was evaluated during the clinical course 
of the disease, and for the remaining 27 the mutational 
analysis was performed retrospectively. In nine WT pa-
tients, an anti- epidermal growth factor receptor (EGFR) 
antibody (cetuximab or panitumumab) was administered 
while two patients with KRAS WT status received pul-
monary stereotactic radiosurgery after relapse. Seven 
patients (9%) developed brain metastases and 43% of 
them had KRAS mutation.
Median follow- up was 82.9 months (range 0.4–180.5). 
At the time of data collection, 48 (64%) of 75 patients 
had died. Median PFS was 13.1 months, median LDFS 
was 32 months while median OS 44.6 months.
KRAS, PTEN, BRAF, and PIK3CA exon 20 
analysis
KRAS mutations (exons 12, 13, and 61) were found in 
26 cases (36%) while 48 cases were WT. Nineteen patients 
(25%) had intact PTEN while the majority (56 patients, 
75%) had loss of protein expression. We did not detect 
any BRAF and PIK3CA exon 20 mutations, while exon 
9 mutations were not investigated because effects on prog-
nosis have been restricted only to exon 20 mutations 
[27].
The relationship between patient characteristics, KRAS 
mutations, and PTEN expression is shown in Table 2. 
Neither KRAS nor PTEN status were significantly associ-
ated with sex and location of primary tumor (colon or 
rectum). Furthermore, no associations were found between 
KRAS and PTEN status and time of onset of lung me-
tastases (synchronous/metachronous), localization 
Table 2. KRAS and PTEN analysis according to clinical factors on evaluable patients.
Characteristics KRAS WT 
N (%)
KRAS MUT 
N (%)
P-value 
KRAS status
PTEN negative 
N (%)
PTEN positive 
N (%)
P- value 
PTEN status
All 48 (64) 27 (36) 56 (75) 19 (25)
Sex
 Female 17 (63) 10 (37) 1.000 17 (63) 10 (37) 0.141
 Male 31 (65) 17 (35) 39 (81) 9 (19)
Primary tumor
 Colon 32 (71) 13 (29) 0.185 34 (76) 11 (24) 1.000
 Rectum 16 (53) 14 (47) 22 (73) 8 (27)
Lung metastases
 Synchronous 12 (67) 6 (33) 1.000 15 (83) 3 (17) 0.368
 Metachronous 35 (64) 20 (36) 39 (71) 16 (29)
Localization
 Unilateral 39 (65) 21 (35) 0.718 45 (75) 15 (25) 1.000
 Bilateral 9 (60) 6 (40) 11 (73) 4 (27)
Chemotherapy prior to lung surgery
 Yes 22 (55) 18 (45) 0.135 34 (85) 6 (15) 0.053
 No 26 (74) 9 (26) 22 (63) 13 (37)
Adjuvant chemotherapy
 No 41 (66) 21 (34) 1.000 45 (73) 17 (27) 1.000
 Yes 5 (62) 3 (38) 6 (75) 2 (25)
Extrapulmonary metastases
 Yes 41 (68) 19 (32) 0.207 44 (73) 16 (27) 0.745
 No 7 (47) 8 (53) 12 (80) 3 (20)
Nodal involvement
 Yes 27 (60) 18 (40) 0.308 33 (73) 12 (27) 0.550
 No 16 (72) 6 (28%) 18 (82) 4 (18)
PTEN, Phosphatase and Tensin Homolog; WT, wild- type; MUT, mutant.
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(unilateral or bilateral), presence or absence of extrapul-
monary metastases, chemotherapy administration prior to 
or after lung surgery and nodal involvement. BRAF and 
PIK3CA exon 20 mutations were not detected.
Survival analysis
With a median follow- up of 82.9 months, we observed 
a median PFS of 13.1 months and a median OS of 
44.6 months. At the univariate analysis, PFS (median 
11.0 months for pretreated patients, 21.4 months for 
nontreated, P = 0.040) and OS (median 28.4 months for 
pretreated, 73.3 months for nontreated, P = 0.005) were 
significantly shorter for patients who had chemotherapy 
prior to lung surgery. Moreover, patients who received 
adjuvant treatment showed longer PFS (median not reached 
for adjuvant treatment, 11.2 months for nonadjuvant 
treatment, P < 0.001) and OS (median not reached for 
adjuvant treatment, 42.8 months for nonadjuvant treat-
ment, P = 0.010). An advantage in PFS (median 13.1 vs. 
11.6 months, P = 0.026) and OS (median 58.0 vs. 
28.5 months, P = 0.039) was also shown in patients with 
unilateral distribution of lung disease compared to bilateral 
disease (Table 3). Moreover, OS was significantly linked 
to KRAS mutational status (median 60.9 months for WT 
patients, 36.6 months for mutant, P = 0.035) (Table 4).
PFS had no statistically significant association with both 
KRAS and PTEN status (Table 4). Moreover, there was 
no difference in the status of KRAS (median 33.1 WT 
vs. 32.0 months mutant, P = 0.402), and PTEN (median 
30.8 negative vs. 39.1 months positive, P = 0.102) in 
determining LDFS between surgery of the primary tumor 
and lung relapse.
A multivariable model was built to correct for the  effect 
of confounders statistically significant in the univariate 
evaluation. Disease localization and presurgical chemo-
therapy were no longer statistically significant and were 
deleted from the model. In the multivariate analysis 
(Table 5), KRAS mutation confirmed its association with 
Table 3. Survival analysis according to baseline and clinical factors on evaluable patients.
Characteristics Median PFS (months) P- value PFS Median OS (months) P- value OS
All 13.1 44.6
Sex
 Female 13.4 0.081 58.0 0.265
 Male 11.2 42.6
Primary tumor
 Colon 13.2 0.308 43.2 0.647
 Rectum 11.6 44.6
Lung metastases
 Synchronous 13.2 0.542 43.2 0.607
 Metachronous 13.1 51.1
Localization
 Unilateral 13.1 0.026 58.0 0.039
 Bilateral 11.6 28.5
Chemotherapy prior to lung surgery
 Yes 11.0 0.040 28.4 0.005
 No 21.4 73.3
Adjuvant chemotherapy
 No 11.2 <0.001 42.8 0.010
 Yes NR NR
Extrapulmonary metastases
 Yes 13.1 0.849 43.8 0.916
 No 10.7 51.1
Nodal involvement
 Yes 13.1 0.824 42.4 0.170
 No 11.7 60.9
PFS, progression- free survival; OS, overall survival; NR, not reached.
Table 4. Median PFS and OS according to KRAS and PTEN status.
Characteristic
Median PFS 
months P- value
Median OS 
months P- value
KRAS
Mutant 13.1 0.483 36.6 0.035
Wild- type 13.1 60.9
PTEN
Positive 14.7 0.832 73.3 0.389
Negative 13.1 42.8
PTEN, Phosphatase and Tensin Homolog; PFS, progression- free survival; 
OS, overall survival.
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a significantly higher risk of death (OS HR 2.17, 95% 
IC 1.19–3.96, P = 0.012). The estimate was adjusted for 
the statistically significant effect of adjuvant chemotherapy 
administration (OS HR 0.10, 95% IC 0.01–0.74, P = 0.024).
Discussion
Our molecular analysis was entirely based on metastatic 
resected lung tissue available from our tissue bank. The 
level of concordance between primary CRC and metastases 
in relation to KRAS status is known to be high, reaching 
a value of 94% as reported by Cejas [14]. However, up 
to now, only two recent studies have analyzed tissue 
specimens from resected lung metastases [8, 12], while 
previous reports on KRAS mutational status and lung 
metastases considered more heterogeneous tumor sources 
[9–11, 13–15] (Table 6). Tie et al. evaluated oncogene 
mutation on liver, lung, and brain metastases from pri-
mary CRC [9], Cejas and Kim analyzed tissue samples 
from both primary tumor and related metastases [10, 14]. 
In contrast, most of the studies evaluated retrospectively 
data of patients whose tumor was tested for KRAS muta-
tion at time of diagnosis [11, 13, 15].
We found a KRAS mutation rate of 36%; this finding 
is similar to the known mutation rate in the primary 
tumor. Seven patients (9%) developed brain metastases.
We did not find any significant association between KRAS 
status and baseline characteristics. Univariate and multivari-
ate analysis showed a significant association between KRAS 
wild- type status and a better OS. Moreover, patients who 
did not have systemic adjuvant treatment were found to 
have a higher risk of death (Table 5). On the other hand, 
neither PFS nor LDFS were associated with KRAS status. 
A reason for this disconnection between OS, LDFS, and 
PFS could be given by the treatments administered before 
and after LM. Indeed, it must be taken into account that 
9 of 48 molecularly assessed KRAS WT patients received 
an anti- EGFR antibody after disease recurrence and could 
have had a longer OS because of these treatments. This 
is consistent with prior studies suggesting a predictive rather 
than prognostic effect of KRAS status [28].
Up to 75% of patients were found to have high PTEN- 
negative tumors. This percentage is higher compared to 
that reported in other series [29–31]. A possible explana-
tion for this could be given by the heterogeneity between 
the different scoring systems used. Patients with intact 
PTEN expression had a longer survival rate compared 
with those whose tumors had loss of PTEN. However, 
the difference in survival was not statistically significant. 
The prognostic role of PTEN loss has not yet been clearly 
defined due to inconsistent results [32]. In patients treated 
with anti- EGFR antibodies, some authors reported shorter 
PFS and OS that reached statistical significance when this 
variable was combined with PIK3CA mutations [31]. On 
the other hand, other authors did not find any associa-
tion between PTEN protein expression and clinical out-
comes [29, 30]. The reason for these different results 
could be the small sample size of the studies, the hetero-
geneity of PTEN expression in primary tumor and meta-
static sites and the evaluation of protein expression by 
IHC with different cutoff and threshold levels used for 
interpretation [33].
These results suggest that mCRC patients undergoing 
lung resection might represent a good prognosis class, in 
which mutant tumors for BRAF and PIK3CA in exon 20 
are excluded by “natural selection”. Confirming our initial 
hypothesis, other studies evaluating surgery of lung me-
tastases from CRC reported a null BRAF mutation rate 
[8, 9], while Renaud et al. reported a 10.6% BRAF muta-
tion rate and identified WT BRAF as a positive prognostic 
Table 5. OS multivariate analysis.
Parameter P- value OS HR 95% HR CI
KRAS
 Mutant versus WT 0.012 2.17 1.19–3.96
Adjuvant treatment
 Yes versus no 0.024 0.10 0.01–0.74
OS, overall survival; HR, hazard ratio; CI, confidence interval; WT, 
wild- type.
Table 6. Previous reported series of mCRC with lung metastases.
Series, year Type of samples Number of samples KRAS mutation rate (%) KRAS mutation 
prognostic value
Cejas et al., 2009 [14] Primary + various metastatic sites 110 59 Shorter DFS
Tie et al., 2011 [9] Various metastatic sites 100 49 Shorter LDFS
Kim et al., 2012 [10] Primary + various metastatic sites 151 45 –
Schweiger et al., 2014 [8] Lung metastases 44 48 Shorter LDFS
Yaeger et al., 2015 [11] Primary + various metastatic sites 918 22 Shorter OS
Pereira et al., 2015 [15] Primary + various metastatic sites 494 70 Shorter LDFS
Renaud et al., 2015 [12] Lung metastases 180 52 Shorter OS
Morris et al., 2014 [13] Primary + various metastatic sites 484 34 Shorter OS
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factor for longer OS [12]. PIK3CA mutation was not 
found to have any prognostic implication both in our 
series and in previous studies [9, 11].
Our findings do not confirm some results obtained in 
other series on molecular analysis on lung and central 
nervous system (CNS) metastases. In fact KRAS mutations 
have been previously associated with a higher CRC met-
astatization rate both in lung parenchyma [8–15] and 
CNS [9, 11], and a significant association between KRAS 
mutations and relapse in the lung have also been reported 
[8, 9, 15]. In our series, we did not assess KRAS status 
on the primary tumor. However, the observed prevalence 
of KRAS mutation is still lower than the figures reported 
in other studies (Table 6) and fits to the known rate of 
KRAS mutation in primary colorectal tumors. The higher 
rates of KRAS mutation reported by different authors 
could be due to the existing high amount of KRAS dis-
cordance between primary tumor and matched lung me-
tastases, formerly reported by Kim et al. [10]. In their 
study, the discordance rate of KRAS mutational status 
between primary and paired metastases other than the 
lung was 12.3%, similarly to what we have previously 
reported [34], while it increased in the case of lung me-
tastases reaching a rate of 32.4% [10]. We did not analyze 
some of the mutations comprised in the RAS pathway, 
namely KRAS exon 4 and NRAS mutations that account 
for up to 9% of the mutations detected in the RAS path-
way [9, 35]. As a matter of fact, our analysis had been 
performed before the data on the role of KRAS exon 4 
and NRAS mutations in CRC became available.
Current National Comprehensive Cancer Network guide-
lines recommend follow- up of CRC patients with chest- 
abdomen- pelvis CT scan to be performed on an annual 
basis [36]. Nevertheless, based on the aforementioned 
findings, more intensive surveillance strategies have been 
suggested for patients with KRAS mutations [9, 14, 15]. 
We cannot come to the same conclusions considering 
the results of our study. Indeed, among patients develop-
ing lung and brain metastases during the follow- up, no 
differences were observed according to KRAS mutational 
status.
Despite the low number of patients treated with adju-
vant chemotherapy (8 patients, 10% of total), this subgroup 
had longer PFS and OS compared to the majority (67 
patients, 90%) who had no postsurgical treatment. 
Administration of adjuvant therapy could constitute a 
prognostic factor for better outcome after LM.
Although not useful in predicting recurrence pattern 
in mCRC, KRAS mutation was found to be associated 
with a statistically significant poorer survival rate both in 
univariate and multivariate analysis. KRAS mutation nega-
tive prognostic role has been already reported in mCRC 
patients undergoing hepatic metastasectomy [20–22], and 
there has been increasing evidence of the prognostic role 
of KRAS mutation in lung metastasectomies so far. KRAS 
may have a prognostic role in mCRC patients with lung 
metastases, but larger studies are needed to assess whether 
mutational status should be considered together with clini-
cal and surgical parameters in the selection of patients 
to candidate for LM.
Conclusions
In mCRC patients with lung metastases, we observed a 
significantly different pattern of metastatic spread between 
KRAS mutant and WT subgroups. In our analysis, KRAS 
mutation was associated with poorer survival in patients 
harboring lung metastases and might be considered having 
a prognostic value. Moreover, administration of adjuvant 
chemotherapy resulted in prolonged PFS and OS and 
could be considered of prognostic relevance as well.
Furthermore, larger and prospective studies are war-
ranted to assess the possible prognostic role of KRAS 
mutational status in patients affected by mCRC and un-
dergoing LM.
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